Donepezil transdermal delivery system
View Patent ↗A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.
1. A transdermal delivery system for systemic delivery of donepezil base to a subject, comprising:
a skin contact adhesive layer to attach the system to the skin of a user, and
a drug reservoir comprised of (i) an acrylate copolymer, (ii) a solvent composition comprising glycerin and one or more of lauryl lactate, sorbitan monolaurate and triethyl citrate, (iii) donepezil HCl, and (iv) an alkaline salt, wherein a therapeutically effective amount of donepezil base is generated in situ in the drug reservoir when the skin contact adhesive layer is attached to skin of the subject by reaction of the donepezil HCl and the alkaline salt wherein the skin contact adhesive layer comprises crosslinked polyvinylpyrrolidone; wherein the alkaline salt in the drug reservoir layer is sodium bicarbonate.
2. The system of claim 1 , further comprising an intermediate layer directly on the contact adhesive layer and disposed between the contact adhesive layer and the drug reservoir.
3. The system of claim 2 , wherein the intermediate layer is a microporous membrane comprising a plurality of pores.
4. The system of claim 3 , wherein the plurality of pores in the microporous membrane contains a solvent composition comprised of one or more of triethyl citrate, sorbitan monolaurate, and lauryl lactate.
5. The system of claim 1 , wherein the skin contact adhesive layer is comprised of a copolymer of acrylic acid/vinyl acetate.
6. The system of claim 1 , wherein the skin contact adhesive layer comprises a contact adhesive layer solvent composition comprising one or more solvents selected from the group consisting of triethyl citrate, sorbitan monolaurate, and lauryl lactate.
7. The system of claim 1 , wherein the skin contact adhesive layer is manufactured from an adhesive formulation that does not comprise donepezil base or a donepezil salt.
8. The system of claim 1 , further comprising a first backing layer in contact with the drug reservoir layer, an adhesive overlay in contact with the first backing layer; and a second backing layer in contact with the adhesive overlay.
9. The system of claim 8 , wherein the adhesive overlay is single layer comprised of an acrylate copolymer.